V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160017370 | 160016588 | 1.85 | 14.3 | null | 2018-10-02 | 2018-10-02 | Cyclophosphamide High Dose | null | null | STS RHABDO VIT0910 VINC IRINO TEMOZ | 100721352 |
| 160017375 | 160016589 | 1.8 | 47 | null | 2019-10-31 | 2019-11-29 | Cisplatin + Paclitaxel | 02 | null | NIRAPARIB | 101613656 |
| 160017378 | 160016591 | null | null | null | 2011-04-18 | 2016-07-05 | Cyclophosphamide + Vincristine | 02 | null | CYCLOPHOSPHAMIDE | 100810764 |
| 160017381 | 160016592 | 1.84 | 61.5 | Curative (C) | 2018-08-14 | 2018-08-23 | OCTOPUS Trial | 02 | null | CONFIRM TRIAL | 100927627 |
| 160017382 | 160016593 | null | 66.5 | Neo-adjuvant (N) | 2020-06-11 | 2020-07-01 | Eribulin | 02 | N | NIRAPARIB | 100578458 |
| 160017385 | 160016594 | 0 | 16.2 | Curative (C) | 2018-05-24 | 2018-06-08 | Niraparib | 02 | N | VINCRISTINE | 100674697 |
| 160017388 | 160016595 | 0 | 17 | null | 2019-09-29 | 2020-02-21 | Cyclophosphamide + Vincristine | 02 | null | TRIAL | 101109548 |
| 160017390 | 160016596 | 0 | 85 | null | 2019-10-07 | 2019-11-03 | Enzalutamide | null | null | ETOPOSIDE + IFOSFAMIDE | 100851729 |
| 160017396 | 160016597 | 0 | 56 | Curative (C) | 2019-11-25 | 2019-12-03 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | CYCLOPHOSPHAMIDE + VINORELBINE | 101280426 |
| 160017398 | 160016598 | 1.5 | 0 | Curative (C) | 2020-11-08 | 2021-01-16 | null | 02 | N | NB HRNBL-1 ISOTRETINOIN | 100262428 |
| 160017404 | 160016599 | 0 | 69.5 | Palliative (P) | 2017-06-01 | 2017-06-29 | Doxorubicin + Ifosfamide | 02 | N | IVA | 100331605 |
| 160017407 | 160016600 | 1.43 | 81 | null | 2017-06-17 | 2017-06-26 | Ifosfamide | 02 | null | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100811708 |
| 160017416 | 160016601 | 1.62 | 13.9 | null | 2018-03-30 | 2018-04-19 | Cisplatin + Doxorubicin | 02 | null | GEMCITABINE | 101132440 |
| 160017418 | 160016602 | 1.55 | 86.2 | Curative (C) | 2020-07-04 | 2020-09-26 | IVADo | 02 | N | OLAPARIB | 100627889 |
| 160017419 | 160016603 | 1.75 | 86.7 | Adjuvant (A) | 2016-06-13 | 2016-06-14 | LENVATINIB | 02 | N | NOT MATCHED | 100343892 |
| 160017422 | 160016604 | 1.62 | 57.4 | null | 2019-11-05 | 2020-04-12 | CONFIRM TRIAL | 02 | null | IFOSFAMIDE | 100534873 |
| 160017429 | 160016605 | 1.76 | 73.6 | Curative (C) | 2016-05-14 | 2017-03-02 | NB HRNBL-1 Isotretinoin | 02 | N | CONFIRM TRIAL | 101753260 |
| 160017434 | 160016606 | 0 | 71 | Curative (C) | 2021-03-24 | 2021-07-22 | Enzalutamide | 02 | N | ETOPOSIDE | 100288250 |
| 160017435 | 160016607 | 1.7 | 52.9 | null | 2019-03-19 | 2019-05-20 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 02 | null | CYCLOPHOSPHAMIDE | 100270980 |
| 160017444 | 160016608 | 1.63 | 27.6 | Palliative (P) | 2019-02-25 | 2019-04-01 | EW EuroEwing 2012 Arm B IE | 02 | N | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 100126331 |
| 160017454 | 160016609 | 1.62 | 49.2 | Curative (C) | null | 2015-03-23 | null | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100695137 |
| 160017457 | 160016610 | 1.63 | 83 | Curative (C) | 2019-01-07 | 2019-01-07 | Cisplatin + Doxorubicin | 01 | N | ABIRATERONE | 100866679 |
| 160017458 | 160016611 | 0 | 57.7 | Palliative (P) | null | 2018-08-06 | Cyclophosphamide + Topotecan | 02 | N | IFOSFAMIDE | 100059797 |
| 160017462 | 160016612 | 1.56 | 66.2 | Palliative (P) | null | 2019-12-29 | Cyclophosphamide + Topotecan | Y | N | CISPLATIN + ETOPOSIDE | 100297998 |
| 160017464 | 160016613 | 0 | 68.1 | Palliative (P) | null | 2018-05-12 | VINCRISTINE | 02 | N | GEMCITABINE | 101623145 |
| 160017466 | 160016614 | 1.68 | 59.6 | Palliative (P) | 2017-09-06 | 2017-09-17 | NB HRNBL-1 COJEC Ind COURSE C | 02 | N | DACARBAZINE + GEMCITABINE | 101683920 |
| 160017471 | 160016615 | 0 | 13.5 | Curative (C) | 2017-09-24 | 2017-09-30 | Niraparib | 01 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101392484 |
| 160017476 | 160016617 | 1.65 | 67.7 | Palliative (P) | 2017-08-23 | 2018-02-06 | EW EuroEwing 2012 Arm B IE | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 101680592 |
| 160017480 | 160016618 | 0 | 78.3 | null | null | null | Etoposide oral | 01 | null | OLARATUMAB | 100968982 |
| 160017488 | 160016619 | 1.7 | 91.5 | Palliative (P) | 2018-06-25 | 2018-06-25 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 01 | N | DACARBAZINE + GEMCITABINE | 101263396 |
| 160017489 | 160016620 | 0 | 90.8 | null | 2019-08-09 | 2019-08-16 | STS Rhabdo VIT0910 Vinc Irinotecan | 02 | null | NOT MATCHED | 101800761 |
| 160017490 | 160016621 | 1.59 | 47 | Palliative (P) | 2019-02-21 | 2019-02-23 | NB HRNBL-1 COJEC Ind COURSE C | 02 | null | EW EUROEWING 2012 ARM B VDC | 100770715 |
| 160017493 | 160016622 | 1.65 | 35.1 | null | 2016-07-04 | 2017-09-18 | ATOMIC-MESO TRIAL | 01 | null | STS RHABDO VIT0910 VINC IRINOTECAN | 101576975 |
| 160017495 | 160016623 | 0 | 61.8 | Palliative (P) | 2018-03-23 | 2018-03-24 | Carboplatin + Etoposide iv&po | 01 | N | NEMO TRIAL | 100568199 |
| 160017502 | 160016624 | 0 | 75 | Palliative (P) | 2019-10-09 | 2019-10-26 | PEMBROLIZUMAB | 02 | N | NB HRNBL-1 BUMEL MAT | 101525945 |
| 160017505 | 160016625 | 1.7 | 13.4 | 03 | 2019-03-18 | 2019-03-19 | CERITINIB | Y | N | EW EUROEWING 2012 ARM A VAI | 101717240 |
| 160017510 | 160016626 | 1.6 | 51.4 | Palliative (P) | 2021-01-25 | 2021-01-28 | Ifosfamide 3g/m2 5 day | 2 | N | NEMO TRIAL | 100415692 |
| 160017517 | 160016627 | 0 | 55.1 | Curative (C) | 2016-12-17 | 2016-12-17 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | PROMISE-MESO TRIAL | 100509910 |
| 160017541 | 160016628 | 1.04 | 85.7 | Curative (C) | 2022-02-17 | 2022-02-17 | EW Rel rEECur Topotecan/Cyclophosphamide | 01 | N | STS RHABDO RMS 2005 VIN CYCLO | 101510823 |
| 160017546 | 160016629 | 1.63 | 60.8 | Palliative (P) | 2019-10-09 | 2019-11-06 | NB Rel CCLG guidelines Cyclo-Topotecan | 02 | N | RMS 2005 TRIAL | 100868010 |
| 160017548 | 160016630 | 1.72 | 75.1 | null | 2016-08-08 | 2016-08-31 | IVA | 02 | null | IVA | 100915208 |
| 160017554 | 160016632 | 1.7 | 65 | null | 2019-12-04 | 2020-01-08 | AFATINIB | 99 | null | SUNITINIB | 101244428 |
| 160017556 | 160016633 | 1.71 | 75 | Curative (C) | 2021-07-24 | 2021-08-07 | Olaparib | 02 | N | TRIAL | 101502820 |
| 160017558 | 160016634 | 0 | 76.5 | null | null | 2019-12-02 | CARBOPLATIN + ETOPOSIDE | 02 | null | OLARATUMAB | 101162573 |
| 160017563 | 160016635 | 1.3 | 98.7 | Palliative (P) | 2020-03-10 | 2020-03-16 | Cyclophosphamide oral | 02 | N | ETOPOSIDE | 100927757 |
| 160017565 | 160016636 | 0 | 65 | Adjuvant (A) | 2019-08-11 | 2019-08-17 | Olaparib | 02 | N | TEMOZOLOMIDE | 101024383 |
| 160017573 | 160016638 | 1.8 | 70 | Curative (C) | 2016-05-24 | 2016-06-17 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | NB HRNBL-1 COJEC IND COURSE C | 100093601 |
| 160017579 | 160016639 | 1.59 | 51.6 | null | 2016-06-03 | 2016-07-19 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | OLARATUMAB | 100917943 |
| 160017581 | 160016640 | 1.61 | 60.3 | Palliative (P) | 2016-11-23 | 2016-12-03 | EW EuroEwing 2012 Arm B VDC | 02 | N | ETOPOSIDE + IFOSFAMIDE | 101161754 |
| 160017582 | 160016641 | 1.86 | 70.2 | Palliative (P) | 2019-01-19 | 2019-08-29 | null | 02 | N | CISPLATIN + DOXORUBICIN | 101358586 |